Obsidian says $324m cash covers amsoki-cel study data due late 2027

Obsidian Therapeutics says its balance sheet should last beyond the next major milestone for amsoki-cel. The company reported $324.4 million in cash with its third-quarter results on 12 November, and said this funds operations into the second half of 2028. It expects topline data from its Agni-01 study by the end of 2027, so the stated runway extends past that readout.

The quarterly net loss was $50.7 million. Obsidian did not give further spending guidance in the material available to CompePharma, and no revenue figures were provided.

The financials came with updated clinical data for amsoki-cel, an engineered tumour-infiltrating lymphocyte therapy, presented at the SITC meeting. In melanoma that had stopped responding to checkpoint inhibitors, the company reported that roughly two-thirds of 15 patients (67%) had a tumour response. Median time before disease progression or death was 8.3 months. Details on the patients' prior treatments and on follow-up length were not provided.

On tolerability, Obsidian pooled data from 37 patients and reported no cases of ICANS, no dose-limiting toxicities and no treatment-related deaths. Enrolment in Agni-01, the cohort intended to support a registration filing, is due to finish by the end of the first quarter of 2027. The efficacy and safety figures are company-reported and come from a small sample, so they are early signals rather than confirmatory evidence.